Reconsidering opioids

Dr Chris Hayes | Hunter Integrated Pain Service





About me



ABOUT ME

My background


PUBLIC HOSPITAL APPOINTMENT HUNTER
INTEGRATED
PAIN SERVICE



Painaustralia Board

Faculty of Pain Medicine, ANZCA (Past Dean)

NSW Agency for Clinical Innovation




Brainman

Website




ABOUT ME

Biopsychosocial model








White R, Hayes C. **Brainman** story.
J Pain Research 2016





ABOUT ME

Behaviour change







Empathy & Boundaries





Today's talk



- 1. EVIDENCE
- 2. TRANSLATION
- 3. POLICY
- 4. RECOMMENDATIONS





Evidence





What happens when opioids are over-used?












- 42 'high quality' RCTs
- Only 9% non-industry funded
- Small benefit for pain and physical function – statistically, but NOT clinically significant
- No difference: nociceptive, neuropathic, nociplastic pain

Busse et al 2018

BETTER CARE	
FVFRYWHFRF	



Difference (95% CI), cm

JAMA | Original Investigation

Opioids for Chronic Noncancer Pain A Systematic Review and Meta-analysis

- Pragmatic RCT opioid v non-opioid medications for 1 year in primary care
- 240 VA patients: mod severe chronic back pain or knee/hip OA, not on opioids
- Mean pain intensity initially 5.4 in both arms
- Pain scores at 1 year worse in opioid arm (4.0) than non-opioid (3.5) (P=0.034)
- Pain interference no different, adverse effects worse in opioid group (P=0.03)



JAMA | Original Investigation

Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain The SPACE Randomized Clinical Trial

Erin E. Krebs, MD, MPH; Amy Gravely, MA; Sean Nugent, BA; Agnes C. Jensen, MPH; Beth DeRonne, PharmD; Elizabeth S. Goldsmith, MD, MS; Kurt Kroenke, MD; Matthew J. Bair; Siamak Noorbaloochi, PhD





- 551 VA patients, long-term opioid therapy for CNCP for ≥ 1 year before discontinuing
- 87% musculoskeletal pain, 11% headache pain including migraines, 6% neuropathic pain



PAIN





Sterling McPherson^{a,b,c}, Crystal Lederhos Smith^{a,b}, Steven K. Dobscha^{d,e}, Benjamin J. Morasco^{d,e}, Michael I. Demidenko^d, Thomas H.A. Meath^{d,f}, Travis I. Lovejoy^{d,e,g,*}






Median pain intensity

- Pre-discontinuation 4.8/10
- Post-discontinuation 4.6/10

McPherson et al. Pain 2018







Translation



What are we doing in Australia?








 Opioid prescriptions dispensed per 100,00 people

Source:

The First Australian Atlas of Healthcare Variation 2015 Australian Commission on Safety and Quality in Health Care



Opioid dispensing	2013-14	2014-15	2015-16	2016-17
Number of PBS opioid prescriptions per 100,000 per year	55,900	57,833	58,600	58,595
Number of defined daily doses of opioid per 1000	16.39	16.32	15.81	15.39

- Dispensing increased by 5%
- Variation in dispensing increased from 4.8 to 5.1x fold
- 2016-17
 - 1.5% of population on an opioid on any given day
 - 3.1 million people had ≥1 opioid prescriptions dispensed (most commonly oxycodone)



BMJ Open Persistence with opioids post discharge from hospitalisation for surgery in Australian adults: a retrospective cohort study


- Dispensing Australian DVA opioid naïve patients admitted to hospital for surgery 2014-2015 (n=24,854)
- 12 month follow-up
- 15.7% discharged on opioids (n=3907)
- 3.9% of those discharged on opioids became long term users (>90 days)

Roughead et al. BMJ Open 2019



Opioid-induced deaths in Australia

- Opioids accounted for just over 3 deaths per day (n=1123)
- Similar to road traffic death rate
- Mostly unintentional overdoses: middle aged males, pharmaceutical opioids, often with other substances





Policy





What shapes the Australian context?





REGULATORY BODIES




POLICY


Cost of Pain Report (2019)

- Deloitte Access Economics
- 2018 3.24 million Australians with CNCP; 68.3% working age
- Cost of \$73.2 billion per annum
- Call for GP education/support and multidisc care

National Strategic Action Plan (2019)

 Endorsed by federal government and opposition








POLICY

STATE HEALTH DEPARTMENTS	Authority for opioid dependency Real time monitoring
THERAPEUTIC GOODS ADMINISTRATION	Approval, indications, PI, CMI, recommendations to sponsors
PHARMACEUTICAL BENEFITS SCHEME	Subsidised medication and authority
MEDICARE BENEFITS SCHEDULE	Item number review Non-medication treatments







Therapeutic Goods Administration


Professor John Skerritt Deputy Secretary Health Products Regulation Group

POLICY

Prescribing indications



Recommendations



RECOMMENDATIONS

What can we do now in our hospitals?

ADDRESS PATIENT EXPECTATIONS

Pre-admission | Admission | Discharge

based on previous 24 hours

SHORT-TERM USE & CESSATION PLAN communicated to patient & GP





RECOMMENDATIONS

What can we do now in primary care?



for chronic non-cancer pain

HAVE A CONVERSATION about opioid weaning

NEGOTIATE TIMING and rate of reduction

SUGGEST A MONTHLY STEP-DOWN of 10-25% of starting dose

IF DRUG DEPENDENCE IS AN ISSUE consider switching to a Drug and Alcohol program





Up next

- Opioid decisions in primary care
- Q&A with Chris and Damien



AUSTRALIAN COMMISSION ON SAFETY AND QUALITY IN HEALTH CARE

bettercareeverywhere.gov.au